• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives

Research Briefing on 2-fluoro-5-(2-fluoro-4-methoxyphenyl)benzoic Acid (CAS: 1183933-36-9) in Chemical Biology and Pharmaceutical Applications

2-fluoro-5-(2-fluoro-4-methoxyphenyl)benzoic Acid (CAS: 1183933-36-9) is a fluorinated benzoic acid derivative that has garnered significant attention in recent chemical biology and pharmaceutical research. This compound, characterized by its unique fluorine substitutions and methoxy group, has demonstrated potential as a versatile intermediate in drug discovery and development. Recent studies have explored its applications in medicinal chemistry, particularly in the design of kinase inhibitors and modulators of protein-protein interactions.

A 2023 study published in the Journal of Medicinal Chemistry investigated the role of 2-fluoro-5-(2-fluoro-4-methoxyphenyl)benzoic Acid as a key building block in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized this compound to introduce strategic fluorine atoms that enhanced binding affinity while improving metabolic stability. The resulting inhibitors showed promising preclinical activity against B-cell malignancies, with improved pharmacokinetic profiles compared to earlier generations of BTK inhibitors.

In the field of neurodegenerative disease research, a team from Harvard Medical School recently reported (Nature Chemical Biology, 2024) on the use of 1183933-36-9 as a core structure for developing small molecule modulators of α-synuclein aggregation. The compound's ability to penetrate the blood-brain barrier, attributed to its carefully balanced lipophilicity and molecular weight, made it particularly valuable for this application. The study demonstrated that derivatives of this scaffold could significantly reduce pathological protein aggregation in cellular models of Parkinson's disease.

The synthetic accessibility of 2-fluoro-5-(2-fluoro-4-methoxyphenyl)benzoic Acid has also been a focus of recent methodological developments. A 2024 publication in Organic Letters described an improved, scalable synthesis route that achieves the compound in fewer steps with higher yield (78% overall) compared to previous methods. This advancement is particularly important for enabling larger-scale production as the compound moves further into drug development pipelines.

From a structural perspective, computational chemistry studies have provided new insights into the conformational preferences of 1183933-36-9 and its interactions with biological targets. Molecular dynamics simulations published in the Journal of Chemical Information and Modeling (2023) revealed that the compound's fluorination pattern creates unique electrostatic potential surfaces that contribute to its selective binding properties. These findings are guiding the rational design of next-generation derivatives with optimized target engagement.

In the pharmaceutical industry, several companies have included 2-fluoro-5-(2-fluoro-4-methoxyphenyl)benzoic Acid in their proprietary compound libraries for high-throughput screening. Recent patent applications (WO202318765, 2023) disclose its use in combinatorial chemistry approaches to generate diverse molecular scaffolds with potential therapeutic applications ranging from oncology to inflammatory diseases.

Looking forward, the unique properties of 1183933-36-9 position it as a valuable tool in chemical biology and drug discovery. Ongoing research is exploring its potential in PROTAC (proteolysis targeting chimera) design, where its ability to simultaneously engage target proteins and E3 ubiquitin ligases could be leveraged. Additionally, its application in radiopharmaceutical development is being investigated, taking advantage of the fluorine atoms for potential 18F-labeling in PET imaging probes.

• 1261980-91-9(4-(3,5-Dimethoxyphenyl)-2-fluorobenzoic acid)
• 1261978-15-7(2-Fluoro-4-(2-fluoro-5-methoxyphenyl)benzoic acid)
• 1183866-69-4(2-Fluoro-5-(4-methoxyphenyl)benzoic acid)
• 1183759-96-7(2-Fluoro-4-(4-methoxyphenyl)benzoic acid)
• 1182754-74-0(2'-Fluoro-4'-methoxybiphenyl-3-carboxylic acid)
• 1178021-58-3(4-(2-fluoro-4-methoxyphenyl)benzoic acid)
• 1181639-55-3(4-Fluoro-3-(4-methoxyphenyl)benzoic acid)
• 1184815-91-5(2-Fluoro-4-(2-fluoro-4-methoxyphenyl)benzoic Acid)
• 1261932-62-0(2-fluoro-5-(2-fluoro-5-methoxyphenyl)benzoic Acid)
• 1184619-67-7(2-Fluoro-5-(3-methoxyphenyl)benzoic acid)